HSA
KROS icon

Hussman Strategic Advisors’s Keros Therapeutics KROS Stock Holding History

Hussman Strategic Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-42,000
Closed -$855K – 306
2025
Q4 		$855K Buy
+42,000
New +$737K 0.21% 193

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Hussman Strategic Advisors's KROS Position: Q1 2026 in Review

Hussman Strategic Advisors sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 42,000 shares — an estimated $855K sold.

Hussman Strategic Advisors first reported a position in KROS in Q4 2025 and held it in 1 quarter. The position peaked at $855K in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Hussman Strategic Advisors reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Hussman Strategic Advisors sold 42,000 Keros Therapeutics shares in Q1 2026, an estimated $855K.
  • Hussman Strategic Advisors first reported a position in Keros Therapeutics in Q4 2025 and held it in 1 quarter.
  • Hussman Strategic Advisors's Keros Therapeutics position peaked at $855K in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Hussman Strategic Advisors's 13F filing for Q1 2026, filed 11 May 2026.